



STATE OF WEST VIRGINIA  
DEPARTMENT OF HUMAN SERVICES  
BUREAU FOR MEDICAL SERVICES

Alex J. Mayer, PhD, MS, PMP  
Cabinet Secretary

Cynthia Beane, MSW, LCSW  
Commissioner

## *Pharmaceutical and Therapeutics Committee*

**January 28<sup>th</sup>, 2026**

Location: Webex only  
Time: Executive Session 2:00 PM - 3:00 PM  
Time: Open Session 3:00 PM – 5:00 PM  
Charleston, WV 25301  
(304) 558-1700

## **AGENDA**

- I. Executive Session- 2:00PM-3:00PM
- II. Call to Order – Call in information for the 3:00 PM Open Session is  
**+1 952-222-7450 meeting code 233 624 270#**  
[Join the meeting now](#)  
Meeting ID: 248 042 737 045 11  
Passcode: E8Hh66oK
- III. Welcome and Introductions
- IV. Housekeeping Items/Updates
  - a. Approval of the October 29<sup>th</sup>, 2025, Minutes
  - b. PDL Compliance/Generic Percent Report Updates
- V. Public Comments (Agenda classes only) – Public comments for this meeting will only be accepted in writing. Comments need to be sent via email to Kristen Boustany ([kristen.n.boustany@wv.gov](mailto:kristen.n.boustany@wv.gov)) no later than January 14<sup>th</sup>, 2026. Comments will be forwarded to committee members prior to the meeting for their review and consideration.

Representatives of drug manufacturers being presented at P&T can register to be on hand to answer any questions put forth by P&T committee members. Registrants must provide a name, email address, name of drug and company they are representing, and provide a completed [disclosure form](#) to the email address above no later than January 14<sup>th</sup>, 2026.



VI. New Business

a. New Drug Overviews

- i. Antidepressants, Other
  - 1. EXXUA (gepirone)
- ii. Antimigraine Agents, Acute
  - 1. BREKIYA (dihydroergotamine mesylate)
- iii. Cytokine and CAM Antagonists
  - 1. OTEZLA XR (apremilast)
  - 2. RHAPSIDO (remibrutinib)
- iv. Hereditary Angioedema Agents, Acute (HAE) **\*NEW CLASS**
  - 1. EKTERLY (sebetralstat)
- v. Hereditary Angioedema Agents, Prophylaxis (HAE) **\*NEW CLASS**
  - 1. ANDEMBRY (garadacimab-gxii)
  - 2. DAWNZERO (donidalorsen)
- vi. NSAID
  - 1. VYSCOXIA (celecoxib)
- vii. Opiate Dependence Treatments
  - 1. ZURNAI (nalmefene)
- viii. Skeletal Muscle Relaxants
  - 1. TONMYA (cyclobenzaprine)

b. Drug Class Reviews

- i. Hereditary Angioedema Agents, Acute (HAE) **\* NEW CLASS**
  - 1. BERINET (C1 esterase inhibitor)
  - 2. FIRAZYR (icatibant)
  - 3. icatibant
  - 4. KALBITOR (ecallantide)
  - 5. RUCONEST (C1 esterase inhibitor, recombinant)
  - 6. SAJAZIR (icatibant)
- ii. Hereditary Angioedema Agents, Prophylaxis **\*NEW CLASS**
  - 1. CINRYZE (C1 esterase inhibitor)
  - 2. HAEGARDA (C1 esterase inhibitor)
  - 3. ORLADEYO (berotralstat)
  - 4. TAKHZYRO (lanadelumab-flyo)
- iii. Pulmonary Artery Hypertension (PAH) Agents
  - 1. ORENITRAM (treprostinil)
  - 2. REMODULIN (treprostinil)
- iv. Ulcerative Colitis Agents, Oral
  - 1. mesalamine

VII. Old Business

VIII. Other Business

IX. Next Meeting –April 22<sup>nd</sup>, 2026- 2:00-5:00 PM VIRTUAL

X. Adjournment